Drug Trial Radar · NCT00199043
Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma
Last checked: Nov 20, 2026Latest source record: Mar 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
May 2003
Primary completion
May 2008
Study completion May 2008
Sponsor
- Lead sponsor
- Goethe UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 20, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study the efficacy and tolerability of two approaches to treat and prevent hyperuricemia is tested in patients with acute lymphoblastic leukemia or high-grade lymphoma with high risk of tumor lysis syndrome. Both arms are compared by randomisation. In one arm patients receive during pre-phase chemotherapy conventional prophylaxis with allopurinol whereas in the other arm Rasburicase is used.
Conditions
- Adult Acute Lymphocytic Leukemia
- High-grade Lymphoma
Interventions
AllopurinolDrug
RasburicaseDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- renal function, uric acid, electrolytes, adverse events and mortality in pre-phase and the two following cycles of chemotherapy, time and dose compliance of chemotherapyTime frame: 3 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital, Medical Dept. II
Frankfurt, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.